Table of Contents

1 Market Overview

• 1.1 Objectives of Research
  • 1.1.1 Definition
  • 1.1.2 Specifications
• 1.2 Market Segment
  • 1.2.1 by Type
    • 1.2.1.1 Purity 98.0%
    • 1.2.1.2 Purity 99.0%
    • 1.2.1.3 Others
  • 1.2.2 by Application
    • 1.2.2.1 Tablet (including dispersible tablet and general tablet)
    • 1.2.2.2 Capsule
    • 1.2.2.3 Others
  • 1.2.3 by Regions

2 Industry Chain

• 2.1 Industry Chain Structure
• 2.2 Upstream
• 2.3 Market
  • 2.3.1 SWOT
  • 2.3.2 Dynamics

3 Environmental Analysis

• 3.1 Policy
• 3.2 Economic
• 3.3 Technology
• 3.4 Market Entry

4 Market Segmentation by Type

• 4.1 Market Size
  • 4.1.1 Purity 98.0% Market, 2013-2018
  • 4.1.2 Purity 99.0% Market, 2013-2018
  • 4.1.3 Others Market, 2013-2018
• 4.2 Market Forecast
  • 4.2.1 Purity 98.0% Market Forecast, 2019-2024
  • 4.2.2 Purity 99.0% Market Forecast, 2019-2024
  • 4.2.3 Others Market Forecast, 2019-2024

5 Market Segmentation by Application

• 5.1 Market Size
  • 5.1.1 Tablet (including dispersible tablet and general tablet) Market, 2013-2018
  • 5.1.2 Capsule Market, 2013-2018
  • 5.1.3 Others Market, 2013-2018
• 5.2 Market Forecast
  • 5.2.1 Tablet (including dispersible tablet and general tablet) Market Forecast, 2019-2024
  • 5.2.2 Capsule Market Forecast, 2019-2024
  • 5.2.3 Others Market Forecast, 2019-2024

6 Market Segmentation by Region

• 6.1 Market Size
  • 6.1.1 Asia-Pacific
    • 6.1.1.1 Asia-Pacific Market, 2012-2018
    • 6.1.1.2 Asia-Pacific Market by Type
    • 6.1.1.3 Asia-Pacific Market by Application
  • 6.1.2 North America
    • 6.1.2.1 North America Market, 2012-2018
    • 6.1.2.2 North America Market by Type
    • 6.1.2.3 North America Market by Application
  • 6.1.3 Europe
    • 6.1.3.1 Europe Market, 2012-2018
    • 6.1.3.2 Europe Market by Type
    • 6.1.3.3 Europe Market by Application
  • 6.1.4 South America
    • 6.1.4.1 South America Market, 2012-2018
    • 6.1.4.2 South America Market by Type
    • 6.1.4.3 South America Market by Application
  • 6.1.5 Middle East & Africa
    • 6.1.5.1 Middle East & Africa Market, 2012-2018
    • 6.1.5.2 Middle East & Africa Market by Type
    • 6.1.5.3 Middle East & Africa Market by Application
• 6.2 Market Forecast
  • 6.2.1 Asia-Pacific Market Forecast, 2019-2024
  • 6.2.2 North America Market Forecast, 2019-2024
  • 6.2.3 Europe Market Forecast, 2019-2024
  • 6.2.4 South America Market Forecast, 2019-2024
  • 6.2.5 Middle East & Africa Market Forecast, 2019-2024

7 Market Competitive

• 7.1 Global Market by Vendors
• 7.2 Market Concentration
• 7.3 Price & Factors
• 7.4 Marketing Channel

8 Major Vendors

• 8.1 AstraZeneca
• 8.2 Teva Pharmaceutical Industries
• 8.3 MSN Laboratories
• 8.4 Cadila Pharmaceuticals
• 8.5 LGM Pharma
• 8.6 Bal Pharma
• 8.7 Changzhou Pharmaceutical Factory
• 8.8 Jingxin Pharm
• 8.9 Zhejiang Hisun Pharmaceutical
• 8.10 HEC Pharm
• 8.11 Lunan Pharmaceutical
• 8.12 Nanjing Frochem Tech
• 8.13 Lianyungang Runzhong Pharmaceutical
• 8.14 Shandong Bechem Chemicals
• 8.15 CTX Life Sciences

9 Conclusion

Summary
Rosuvastatin calcium (CAS 147098-20-2, molecular formula being C44H54CaF2N6O12S2) is the active pharmaceutical ingredient for the once-a-day dyslipidaemia treatment Crestor, it is one approved API which can be used to reduce the risk of heart attack and stroke.Rosuvastatin calcium is a hygroscopic powder suitable for the manufacture of tablets and capsules. The appropriate excipients need to be added. The particle size of the product is designed in such a way that optimal dissolution can be obtained (depending on formulation).Rosuvastatin Calcium is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It works by slowing the production of cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body. Rosuvastatin Calcium was developed by Shionogi and has been formulated into finished oral dosage form and marketedby AstraZeneca as Crestor, Abbott Laboratories as R2.
The global Rosuvastatin Calcium market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.
Based on products type, the report describes major products type share of regional market. Products mentioned as follows:
Purity 98.0%
Purity 99.0%
Others
Leading vendors in the market are included based on profile, business performance etc. Vendors mentioned as follows:
AstraZeneca
Teva Pharmaceutical Industries
MSN Laboratories
Cadila Pharmaceuticals
LGM Pharma
Bal Pharma
Changzhou Pharmaceutical Factory
Jingxin Pharm
Zhejiang Hisun Pharmaceutical
HEC Pharm
Lunan Pharmaceutical
Nanjing Frochem Tech
Lianyungang Runzhong Pharmaceutical
Shandong Bechem Chemicals
CTX Life Sciences
Based on Application, the report describes major application share of regional market. Application mentioned as follows:
Tablet (including dispersible tablet and general tablet)
Capsule
Others
Based on region, the report describes major regions market by products and application. Regions mentioned as follows:
Asia-Pacific
North America
Europe
South America
Middle East & Africa